Oryza250 ml

Oryza is indicated for the symptomatic relief of pain and inflammation associated with conditions of the mouth and throat. Its use is generally supported by clinical experience and inclusion in national/international formularies for topical oromucosal use, rather than by large modern randomized trial programs, and it is intended for short-term symptomatic relief rather than for treating the underlying cause.

• Established/labeled uses:
  • Sore throat and pharyngitis (viral or non-specific), for symptomatic pain relief
  • Gingivitis and other painful inflammatory conditions of the gums and oral mucosa
  • Aphthous ulcers (mouth ulcers) and stomatitis
  • Pain and discomfort after dental extraction, oral surgery, or denture fitting
  • Pain associated with oral and oropharyngeal candidiasis or other mucosal irritation (used as adjunct symptomatic care, not as antifungal/antibacterial treatment)
• Guideline/adjunct use: Used as an adjunct measure for radiotherapy- or chemotherapy-induced oral mucositis in some cancer-supportive-care protocols, for symptomatic pain relief alongside standard mucositis care.
• Not a substitute for causal treatment: Oryza relieves pain and inflammation but does not treat the underlying infection (e.g., streptococcal pharyngitis or oral candidiasis); a physician should evaluate persistent, severe, or recurrent symptoms.

Each formulation of Benzydamine Hydrochloride contains benzydamine hydrochloride as the active ingredient. Common presentations include:

• Oral rinse/mouthwash/gargle solution: Benzydamine Hydrochloride 0.15% w/v
• Oromucosal spray: Benzydamine Hydrochloride 0.15% w/v
• Lozenges (in some markets): Benzydamine Hydrochloride 3 mg per lozenge

Formulations may also contain excipients such as ethanol, glycerin, flavoring, and coloring agents; check the specific product label for the complete excipient list, especially in patients with alcohol sensitivity or in children.

Oryza is a locally-acting, non-steroidal anti-inflammatory drug (NSAID) of the indazole chemical class, formulated for topical use in the mouth and throat. Unlike systemic NSAIDs, it is applied directly to the oral/pharyngeal mucosa as a mouthwash, gargle, spray, or lozenge, where it produces analgesic, anti-inflammatory, and local anesthetic effects with only minimal systemic absorption.

It is widely used across Asia, Europe, and other regions (including Bangladesh) for short-term symptomatic relief of sore throat, mouth ulcers, gum inflammation, and post-procedural oral pain, and is available both as a single-ingredient product and in combination with antiseptics such as chlorhexidine.

Oryza belongs to the class of topical/locally-acting non-steroidal anti-inflammatory drugs (NSAIDs) of the indazole derivative group, also classified as an oromucosal analgesic and local anesthetic used in otorhinolaryngology and dentistry.

Benzydamine Hydrochloride is an indazole-derivative NSAID that, unlike most other NSAIDs, is used almost exclusively by the topical/oromucosal route. Its pharmacological actions include:

• Anti-inflammatory action: Inhibits the synthesis of pro-inflammatory prostaglandins and reduces the production of pro-inflammatory cytokines (e.g., TNF-alpha), and stabilizes cell membranes, reducing local inflammation.
• Analgesic action: Reduces local pain signaling associated with inflamed oral and pharyngeal mucosa.
• Local anesthetic action: Produces a mild surface-anesthetic effect on the mucosa, giving a numbing/tingling sensation and rapid symptomatic relief distinct from its anti-inflammatory effect.
• Antiseptic/antimicrobial action: Shows some in-vitro activity against certain bacteria and fungi (including Candida species), though it is not used as a primary antimicrobial therapy.

Because it is applied topically at low concentration, systemic absorption of Benzydamine Hydrochloride is minimal when used as directed, which limits systemic NSAID-type side effects but does not eliminate the risk of local irritation or hypersensitivity reactions.

For the oral rinse/mouthwash/gargle form of Oryza, measure the recommended volume, rinse or gargle in the mouth/throat for 20–30 seconds, then spit out completely — do not swallow. Dilute with an equal volume of water first if stinging or burning is uncomfortable.

For the oromucosal spray, direct the spray onto the painful area of the mouth or throat as directed; avoid inhaling the spray directly and avoid contact with the eyes.

For lozenges, allow the lozenge to dissolve slowly in the mouth; do not chew or swallow whole.

Do not eat or drink immediately after use if numbness of the mouth/throat is present, to avoid accidental biting of the tongue or cheek or difficulty swallowing.

Because Oryza is applied topically with minimal systemic absorption, clinically significant systemic drug interactions are not well established. Reported considerations include:

• Other topical oral products: Concurrent use of multiple oromucosal antiseptic/anesthetic products may increase the risk of local irritation or additive numbness; space out use of different oral products where possible.
• NSAID/aspirin sensitivity: In patients with known hypersensitivity or bronchospastic reactions to aspirin or other NSAIDs, there is a theoretical risk of cross-reactive hypersensitivity even with topical Oryza; such patients should use it cautiously and seek medical advice first.

No clinically significant interactions with systemic medications (e.g., anticoagulants, antihypertensives) have been well documented for topical Oryza, given its low systemic bioavailability when used as directed.

Oryza is generally well tolerated when used topically as directed. Reported adverse effects include:

• Common: Local numbness or tingling sensation of the mouth/throat (an expected local anesthetic effect), mild stinging or burning sensation on application (often reduced by dilution), dry mouth.
• Less common: Nausea, throat irritation, cough, headache, or drowsiness.
• Rare but serious: Hypersensitivity reactions including urticaria (hives), skin rash, angioedema (swelling of the lips, face, or eyelids), bronchospasm, and, rarely, severe anaphylactic reactions — these require immediate discontinuation and urgent medical attention.

The safety of Oryza during pregnancy has not been well established in controlled studies. Although systemic absorption from topical/oromucosal use is low, Oryza should be used during pregnancy only if clearly needed and if the potential benefit justifies any potential risk to the fetus; a physician should be consulted before use.

It is not known whether topically applied Oryza is excreted into breast milk in clinically significant amounts. As a precaution, breastfeeding mothers should consult a physician before using Oryza, particularly for anything beyond occasional, short-term use.

Oryza is intended for short-term symptomatic use. Observe the following precautions:

• Do not use for longer than the recommended duration (typically up to 7 days) without medical or dental evaluation of the underlying condition; persistent or worsening throat/mouth pain, fever, or difficulty swallowing warrants prompt medical assessment.
• Avoid contact with the eyes; if accidental ocular exposure occurs, rinse immediately and thoroughly with water and seek medical advice if irritation persists.
• Dilute the mouthwash/gargle formulation with an equal volume of water if stinging or burning occurs.
• Use caution in patients with known hypersensitivity to aspirin or other NSAIDs (see Contraindications) and in patients with asthma, due to a theoretical risk of bronchospasm.
• Avoid eating or drinking immediately after use while numbness is present, to prevent inadvertent biting of the tongue/cheek.
• Use in young children only under medical or dental guidance and according to the age restrictions of the specific formulation, due to the risk of accidental swallowing or inability to reliably gargle/spit.
• Some formulations contain alcohol (ethanol); use with caution in patients who must avoid alcohol and in young children.

Because Oryza is used topically with low systemic absorption, significant systemic toxicity is unlikely with normal use. However, accidental swallowing of a large amount, or intentional misuse of concentrated oral formulations, has been associated with gastrointestinal upset (nausea, vomiting), agitation, dizziness, ataxia, and, at high doses, central nervous system effects such as hallucinations or seizures.

If overdose or significant accidental ingestion is suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Do not induce vomiting unless specifically instructed by a medical professional.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of the reach and sight of children.

Renal impairment: No formal dose adjustment has been established for topical Oryza due to its minimal systemic absorption; nonetheless, caution is advised in patients with significant renal impairment, particularly with frequent or prolonged use.

Hepatic impairment: Similarly, no specific dose adjustment is established; use with caution in patients with significant hepatic impairment.

Elderly: No specific dose adjustment is required in elderly patients; use as per standard adult dosing with attention to the general precautions above.

Children: Use is restricted by formulation and age (see Dosage and Administration and Pediatric Use); not recommended in young children who cannot reliably gargle, spit, or use a spray safely.

Patients with asthma or aspirin/NSAID hypersensitivity: Use with caution due to a theoretical risk of cross-reactive bronchospasm or hypersensitivity (see Contraindications and Precautions).

Oryza is intended for short-term, symptomatic use, generally for no more than 7 consecutive days. If symptoms of sore throat, mouth pain, or inflammation do not improve within a few days, worsen, or recur frequently, treatment should be stopped and a physician or dentist consulted to evaluate the underlying cause rather than continuing self-treatment with Oryza.

Benzydamine Hydrochloride is classified as a topical non-steroidal anti-inflammatory drug (NSAID) of the indazole derivative chemical class, functioning as an oromucosal analgesic, anti-inflammatory, and local anesthetic agent.

Benzydamine Hydrochloride acts locally at the site of application in the mouth and throat by inhibiting prostaglandin synthesis and reducing pro-inflammatory cytokine production (anti-inflammatory effect), interrupting local pain signal transmission (analgesic effect), and producing a mild surface local-anesthetic effect on the mucosa (numbing/tingling). These combined actions reduce pain, swelling, and discomfort at the mucosal surface, with only minimal drug reaching the systemic circulation when used as directed.

The use of Oryza in children depends on the specific formulation:

• Mouthwash/gargle (0.15%): Generally not recommended in children under 12 years of age, as younger children may be unable to gargle reliably without swallowing the solution.
• Oromucosal spray (0.15%): Not recommended in children under 6 years of age. In children aged 6–12 years, use only under medical supervision with a reduced, weight-appropriate number of sprays as directed on the specific product label; safety and efficacy of the spray have not been fully established for all pediatric age groups outside the labeled range.
• Lozenges: Not recommended in young children due to the risk of choking; safety and efficacy in children have not been established for most lozenge products.

Parents/caregivers should supervise use in children and consult a physician or dentist before use in any child, particularly those under 12 years of age.